Revisiting the cardiovascular risk of hydroxychloroquine in RA

Yves-Marie Pers; Guillaume Padern

doi:10.1038/s41584-020-00521-x

Back

Revisiting the cardiovascular risk of hydroxychloroquine in RA

Journal article

Open access

Revisiting the cardiovascular risk of hydroxychloroquine in RA

Yves-Marie Pers and Guillaume Padern

Nature Reviews Rheumatology, Vol.16(12), pp.671-672

12/2020

DOI: https://doi.org/10.1038/s41584-020-00521-x

PMCID: PMC7525224

PMID: 32999492

Abstract

Anti-Bacterial Agents

Anti-Infective Agents

Hydroxychloroquine

SARS-CoV-2

Safety

Sulfasalazine

Time Factors

Antimalarials

Arthritis, Rheumatoid

Azithromycin

COVID-19

Cardiovascular Diseases

Drug Therapy, Combination

Heart Disease Risk Factors

Humans

Cardiac toxicity can be induced by hydroxychloroquine, especially when used in combination with azithromycin. Interest in hydroxychloroquine and azithromycin as potential therapies for COVID-19 has renewed concerns about the possible cardiovascular risk these drugs present to patients with rheumatoid arthritis.

Files and links (2)

url

Find in HALView

url

https://doi.org/10.1038/s41584-020-00521-xView

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: Revisiting the cardiovascular risk of hydroxychloroquine in RA
Creators - without role: Yves-Marie Pers - Université de Montpellier, Cell souches plasticité cellul régénérat tissulaire immuno des maladies inflamm - IRMB
Guillaume Padern - Université de Montpellier, Cell souches plasticité cellul régénérat tissulaire immuno des maladies inflamm - IRMB
Publication Details: Nature Reviews Rheumatology, Vol.16(12), pp.671-672
Identifiers: 9935667709311
Academic Unit: Cell souches plasticité cellul régénérat tissulaire immuno des maladies inflamm - IRMB
Language: English
Resource Type: Journal article
Local Fields: hal-03338004